GENFIT: Publication of the 2019 Universal Registration Document and the 2019 Annual Report on Form 20-F
27 Mai 2020 - 6:55PM
GENFIT: Publication of the 2019 Universal Registration Document and
the 2019 Annual Report on Form 20-F
Lille (France), Cambridge
(Massachusetts, United States), May 27, 2020 – GENFIT
(Euronext: GNFT - ISIN: FR0004163111), a late-stage
biopharmaceutical company dedicated to improving the lives of
patients with metabolic and liver diseases, today announced the
filing of its 2019 Universal Registration Document with the
Autorité des marchés financiers (AMF) and its Annual Report on Form
20-F for the year ended December 31, 2019 with the U.S. Securities
and Exchange Commission (SEC).
These annual reports are available to the
public free of charge in accordance with applicable regulations and
may be viewed at and downloaded from GENFIT’s website at
https://ir.genfit.com/. The 2019 Registration Document is also
available on the AMF’s website: www.amf-france.org and the
Annual Report on Form 20-F is available on the website of the SEC
(www.sec.gov).
GENFIT’s 2019 Universal Registration Document
includes, in particular, the annual financial report, the annual
Board of Directors’ management report, the Board of Directors’
report on corporate governance, the Statutory Auditors’ reports on
the annual and consolidated financial statements and related-party
agreements and the table summarizing the fees paid to the Statutory
Auditors.
As a result of staffing constraints, remote work
transitions, mobilization of our finance, legal and clinical teams
normally involved in the drafting of our annual reports on key
business continuity efforts and coordination of the Company’s
response to the COVID-19 pandemic, and reliance on certain
third-parties to assist us in the production of the annual reports
who were also impacted by COVID-19, the publication of our annual
reports was delayed, as previously disclosed in our press release
on April 29, 2020.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to the discovery and development of innovative
therapeutic and diagnostic solutions in metabolic and liver related
diseases where there are considerable unmet medical needs,
corresponding to a lack of approved treatments. GENFIT is a leader
in the field of nuclear receptor-based drug discovery, with a rich
history and strong scientific heritage spanning more than two
decades. Its most advanced drug candidate, elafibranor, is
currently being evaluated in a pivotal Phase 3 clinical trial
(“RESOLVE-IT”) as a potential treatment for NASH and GENFIT plans
to initiate a Phase 3 clinical trial of elafibranor in patients
with PBC. As part of GENFIT’s comprehensive approach to clinical
management of patients with NASH, the Company is also developing a
new, non-invasive blood-based diagnostic test, NIS4™, which, if
approved, could enable easier identification of patients with NASH.
With facilities in Lille and Paris, France, and Cambridge, MA, USA,
the Company has approximately 200 employees. GENFIT is a publicly
traded company listed on the Nasdaq Global Select Market and on
compartment B of Euronext’s regulated market in Paris (Nasdaq and
Euronext: GNFT). www.genfit.com
CONTACT
GENFIT | Investors
Naomi EICHENBAUM – Investor Relations | Tel: +1
(617) 714 5252 | investors@genfit.com
PRESS RELATIONS | Media
Hélène LAVIN – Press relations | Tel: +333 2016
4000 | helene.lavin@genfit.com
GENFIT | 885 Avenue Eugène Avinée, 59120
Loos - FRANCE | +333 2016 4000 |
www.genfit.com
- GENFIT: Publication of the 2019 Universal Registration Document
and the 2019 Annual Report on Form 20-F